Can Cernilton help treat benign prostatic hyperplasia (BHP)?

Advertisement
Advertisement

A number of products derived from pollen extracts have been proposed as treatments for benign prostatic hyperplasia (BPH). Most studies of these products involve a drug called Cernilton. Animal studies using Cernilton have shown that it can reduce the size of the prostate and inhibit hormone-stimulated growth.

A randomized, placebo-controlled trial of 60 men treated for BPH over six months showed that 69% of men who took Cernilton -- but only 29% of men who took a placebo -- felt that their condition had improved. There was improvement in some but not all symptoms -- nocturia and the sense of incomplete emptying were better with Cernilton -- but there was no difference in peak urinary flow rates between the two groups. Cernilton did lead to a decrease in prostate size.

Another four-month study compared Cernilton with Tandenan, which is a Pygeum Africanum product. The study involving 89 men showed that there was a greater improvement in symptoms, urinary flow rate, and post-void residual volume in men who took Cernilton than in men who took Tandenan.

The effectiveness of pollen extracts, such as rye pollen, to treat BPH remains to be proved. More studies of longer duration are needed to establish these extracts as a legitimate treatment for BPH.

Continue Learning about Enlarged Prostate Treatment

Important: This content reflects information from various individuals and organizations and may offer alternative or opposing points of view. It should not be used for medical advice, diagnosis or treatment. As always, you should consult with your healthcare provider about your specific health needs.